News

Formed last spring by health insurer UnitedHealth Group, the alliance is anchored by Diabetes Prevention Program and Diabetes Control Program. Both of them have been tested through controlled

Schniepp is expected to take up the responsibility for cGMP compliance of OsoBio’s facility. Additionally, quality-related matters concerning validation as well as regulatory affairs, records and filings fall

The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) by AstraZeneca. The second milestone marks the completion

Intercept is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in

TRO40303 is indicated to reduce the cardiac reperfusion injury that contributes to the morbidity and mortality seen post myocardial infarction (MI). TRO40303 study is expected to recruit healthy

Income from operations was $12.8m for the full year ended 30 June 2010, compared to $10m for the year ago period. For the full year ended 30 June

The increase in sales revenue resulted from the increase of the company’s sales volume and selling prices. Net profit for fiscal 2010 was $3.2m or 0.17 per share

Medtronic’s IN.PACT drug-eluting balloons feature a hydrophilic coating called FreePac that frees and separates paclitaxel molecules, facilitating their absorption into the vessel wall to mitigate re-narrowing of the

The company has posted a net loss of $413,864 for the year ended 30 June 2010, or $ 0.06 loss per diluted share, compared to net loss of